Research Licence. Commencing on the Effective Date, and solely to the extent that it is agreed in any Collaboration Program or Research Pool Program that GSK should conduct work under the applicable Development Plan or Research Pool Program, Adaptimmune shall grant and hereby grants to GSK a non-exclusive licence in the Territory under the Adaptimmune Background and Adaptimmune’s interests in Collaboration Program IP, to ***Portions of this page have been omitted pursuant to a request for Confidential Treatment and filed separately with the Commission. the extent necessary for GSK’s performance of the Collaboration Program or Research Pool Program. The licence under this Section 5.4 shall expire on the earlier of (a) the date on which Adaptimmune rejects a Nomination Notice in accordance with Section 5.3.2; or (b) an exclusive licence being granted following exercise of the relevant Option, as applicable; or (c) expiration of the applicable Option Period without exercise of the Initial Program Option or Collaboration Program Option, as applicable; or (d) Completion of the Collaboration Program or Research Pool Program. The licence under this Section 5.4 shall be sub-licenseable to GSK’s Affiliates and subcontractors to the extent such Affiliates and subcontractors are performing any obligations under any Collaboration Program or the Research Pool Program.
Research Licence. Commencing on each Nomination Date for each Collaboration Program, and solely to the extent that it is agreed in any Collaboration Program that GSK should conduct work under the applicable Research Plan, Immunocore shall grant and hereby grants to GSK a non-exclusive licence in the Territory under the Immunocore Background, Immunocore Foreground, Joint Foreground and Platform Rights to the extent necessary for GSK’s performance of the Collaboration Program. The licence under this Section 5.4 shall expire on the earlier of (a) the date on which Immunocore rejects a Nomination Notice in accordance with Section 5.3.2; or (b) an exclusive licence being granted following exercise of the Initial Program Option or Collaboration Program Option, as applicable; or (c) expiration of the applicable Initial Program Option Period or Collaboration Option Period without exercise of the Initial Program Option or Collaboration Program Option, as applicable; or (d) Completion of the Collaboration Program. The licence under this Section 5.4 shall be sublicenseable to GSK’s Affiliates to the extent such Affiliates are performing any obligations under any Collaboration Program.
Research Licence. Commencing on the Amendment Effective Date and continuing until the date [***] from the Amendment Effective Date, Immunocore hereby grants to GNE a royalty-free, non-transferable, non-sublicenseable, non-exclusive research license under Immunocore’s rights in the Immunocore Background IP, the Immunocore Foreground IP, and the Joint IP solely for the purposes of completing any research related to MAGE-A4 and [***] being undertaken by GNE as at the Amendment Effective Date pursuant to the licence set out in Section 4.1.1(a) of the Existing Agreement for the purpose of jointly publishing the results. The Alliance Managers will be responsible for jointly agreeing any research and publication to be undertaken pursuant to this licence. Section 11.6 of the Agreement shall apply to any publication or disclosure of papers, presentations, abstracts or other written or oral presentation regarding results of and other information generated by GNE as a result of the exercise of its rights pursuant to this paragraph 7 except that in the event that of any disagreement by the Parties concerning such publication, the matter shall be referred for determination by the Alliance Managers.
Research Licence. In consideration for:
(a) assignment of the Assigned Technology and Assigned Materials to Angioblast;
(b) any exclusive licence to Unassignable Technology and Unassignable Materials; and
(c) any non-exclusive licence to Non-Exclusive Unassignable Materials, Angioblast hereby grants Medvet a non-exclusive, perpetual, irrevocable, royalty free licence to use the Technology and Materials for non-commercial, internal research and academic research effective from the date of this Deed provided Medvet will not use the Technology and Materials commercially or enter contractual obligations with third parties that is either inconsistent with Angioblast’s rights under this Deed or relates in any way to the Technology and Materials, and further provided that Angioblast will own all research results and Intellectual Property Rights relating thereto developed or created for or on behalf of Medvet pursuant to Medvet’s licence under this clause 6.
Research Licence. (a) By this document MEPL grants to Novogen Research a non-exclusive, irrevocable, royalty-free licence under the rights granted to MEPL under the Licensed Intellectual Property to:
(i) conduct its own research and development on and in relation to any Licensed Product; and
(ii) use, reproduce, apply, develop, modify and enhance the Licensed Know How for the purpose of conducting its own research and development on and in relation to any Licensed Product.
(b) Novogen Research may not assign, dispose of, transfer, or grant any sub-licence under the rights granted to it in paragraph (a) to any person other than a Novogen Company without the prior written consent of MEPL.
Research Licence. XXXXXXX hereby grants to LAVA a non-exclusive, worldwide licence under the XXXXXXX Technology, solely to conduct activities allocated to LAVA under the Research Plan during the Research Term.
Research Licence. The Research Licence will come into effect on the Effective Date and unless terminated earlier in accordance with this clause or under the general law will continue in force until the earlier of:
(a) the Licensee giving OGT written notice of termination no less than 3 months prior to the intended termination date; or
(b) the end of the Patent Term.
Research Licence. Research license grants you a nonexclusive, non transferable limited license to use the Product only for the purpose of developing, testing, prototyping and demonstrating your application(s), and not for any other purpose.
Research Licence. Subject to You complying with the conditions in clause 4 and paying the applicable licence fees in accordance with clause 7, the University will issue You with a product serial key (Product Key) and grants to You a limited, non-exclusive, non-transferable, revocable licence (excluding any right of sub-licence) to use the Software:
(a) in a manner consistent with its design and documentation;
(b) for internal research purposes within a degree-granting institution only;
(c) on two computers owned by You and located within Your premises; and
(d) from the date the Product Key is activated on the Software until the licence is terminated (Research Licence). You acknowledge that the Software under the Research Licence does not include future updates to the Software and that updates to the Software are only available upon payment of upgrade fees set at the applicable time.
Research Licence
